|Bid||73.17 x 900|
|Ask||73.20 x 1200|
|Day's Range||72.82 - 73.56|
|52 Week Range||36.82 - 73.77|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||55.65|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||0.16 (0.22%)|
|Ex-Dividend Date||May 28, 2021|
|1y Target Est||73.08|
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.
Bruker Corporation (Nasdaq: BRKR) will host a Virtual Investor Day on June 17th, 2021, starting at 10:00 AM Eastern Daylight Time. The Investor Day will be in a virtual format, with no option to attend in person.
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the FluoroType SARS-CoV-2 varID Q assay – a quantitative LiquidArray® mid-plex PCR panel. This novel assay panel also detects several important mutations to enable laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The very sensitive FluoroType SARS-CoV-2 varID Q diagnostic test detects the SARS-CoV-2 virus using three independent gene targets for high assay robustness, even in c